Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14-day randomized double-blind placebo-controlled crossover trial of intranasal GSK256066 in seasonal allergic rhinitis
2005-005340-12Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK256066 in seasonal allergic rhinitis (SAR) (2 arms), sponsored by GSK. Primary endpoint: Weighted mean total nasal symptom score (TNSS) 0–6h post-dose on Day 14. Started Jan 2006; status: completed.
02
Drugs
GSK256066
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2005-005340-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005340-12.